500702-95-4

Upstream product

• 119125-26-7 (Z)-but-2-ene-1,4-diyl bis(2,2-dimethylpropanoate) 
• 140-28-3 N,N'-Dibenzylethylenediamine 
• 783368-59-2 (Z)-1,4-bis(i-propoxycarbonyloxy)-2-butene 
• 17199-29-0 (S)-Mandelic acid 
• 126544-40-9 racemic-1,4-Dibenzyl-2-vinylpiperazine 
• 25260-60-0 cis-1,4-bis(acetyloxy)but-2-ene 

Downstream Products

• 612503-10-3 (R)-mandelic acid salt of the (S)-1,4-dibenzyl-2-vinylpiperazine 
• 612503-09-0 (S)-mandelic acid salt of the (R)-1,4-dibenzyl-2-vinylpiperazine 

Relevant academic research and scientific papers

Novel chiral xylofuranose-based phosphinooxathiane and phosphinooxazinane ligands for palladium-catalyzed asymmetric tandem allylic allylation

Novel chiral xylofuranose-based phosphinooxathiane and phosphinooxazinane ligands have been synthesized and found to be effective ligands for palladium-catalyzed asymmetric tandem allylic allylations of 1,4-diacetoxy-cis-2-butene with 2-(benzylamino)ethanol or 1,2-bis[benzylamino]ethane to give chiral 4-benzyl-2-vinylmorpholine (94% ee) or 1,4-dibenzyl-2-vinylpiperazine (70% ee).

Palladium-catalyzed asymmetric tandem allylic substitution using chiral 2-(phosphinophenyl)pyridine ligand

Palladium-catalyzed asymmetric tandem allylic substitution of (Z)-1,4-diacyloxy- and (Z)-1,4-bis(alkoxycarbonyloxy)-2-butene (2a-c) using 2-(phosphinophenyl)pyridine 1 as chiral ligand provided optically active six-membered 2-vinyl-1,4-diheterocyclic comp

PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES

Described herein are compounds of formula (I) wherein: is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, S, and O; Alk is (C1-4) alkylene or hydroxy substituted (C1-4) alkylene; X is oxygen or sulfur; R1 is hydrogen, (C1-6) fluoroalkyl, (C3-6) cycloalkyl, or (C1-4) alkyl, wherein the (C1-4) alkyl is unsubstituted or substituted with hydroxy, methoxy, ethoxy, OCH2CH2OH, or -CN; R2 is H, halogen, (C1-6) fluoroalkyl, (C1-6) cycloalkyl, OR4, SR4, N02, CN, COR4, C(O)OR4, CONR5R6 , NR5R6, S02NR5R6, NR5COR4, NR5SO2R4, optionally substituted aromatic, or (C1-6) alkyl, wherein (C1-6) alkyl is unsubstituted or substituted with a hydroxy group; R3 is hydrogen, (C1-6) fluoroalkyl, (C2-6) alkenyl, Ar, (C1-4)alkyl-Ar, or (C1-4) alkyl wherein (C1-4) alkyl is unsubsituted or substituted with a phenyl; R4 is hydrogen, (C1-6 alkyl, (C1-6) fluoroalkyl, or optionally substituted aromatic; R5 and R6 are independently hydrogen, (C1-6) alkyl, or optionally substituted aromatic, R7 is hydrogen, (C1-6) alkyl, (C1-6) fluoroalkyl, or optionally substituted aromatic; R8 and R9 are independently hydrogen, (C1-6) alkyl, or optionally substituted aromatic; Ar is optionally substituted phenyl, napthyl, monocyclic heteroaromatic or bicyclic heteroaromatic; Z1 and Z2 are independently selected from hydrogen, halogen, (C1-6) alkyl, (C1-6) fluoroalkyl, OR7, SR7, NO2, CN, COR7, CONR8R9, NR8R9, and optionally substituted aromatic; and all salts, solvates, optical and geometric isomers, and crystalline forms thereof. Also, described are the use of the compounds of formula (I) as antagonists of the dopamine D2 receptor and as agents for the treament of psychosis and bipolar disorders, and pharmaceutical formulations of the compounds of formula (I).

PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS

Described herein are antipyschotic compounds of formula (I) wherein, A is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, O, and S; Alk is (C1-4) alkylene optionally substituted w